Researcher Profile

Researcher Profile

Raymond Hohl, MD, PhD

Raymond Hohl, MD, PhD

University Professorship in Oncology, Department of Medicine
Professor, Department of Pharmacology
Scientific Program:Experimental Therapeutics
Disease Teams:
Bone Marrow Transplantation
Leukemia and Lymphoma
rjh35@psu.edu
View Website

Research Interests

  • Neoplasms
  • Terpenes
  • Therapeutics
  • Lovastatin
  • Proteins
  • Leukemia
  • Prenylation
  • Diphosphonates
  • Pharmacokinetics
  • Protein Prenylation
  • Farnesyltranstransferase
  • Cell Line

Clinical Trials

MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Rearrangements
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor).
Blood and Bone Marrow Collection from Patients with Hematological Malignancies for Study of Anti-Tumor Immunity

Recent Publications

2019

Huang, X, Sterling, NW, Du, G, Sun, D, Stetter, C, Kong, L, Zhu, Y, Neighbors, J, Lewis, M, Chen, H, Hohl, R & Mailman, R 2019, 'Brain cholesterol metabolism and Parkinson's disease', Movement Disorders, vol. 34, no. 3, pp. 386-395. https://doi.org/10.1002/mds.27609
Weissenrieder, JS, Neighbors, J, Mailman, R & Hohl, R 2019, 'Cancer and the dopamine D2 receptor: A pharmacological perspective', Journal of Pharmacology and Experimental Therapeutics, vol. 370, no. 1, pp. 111-126. https://doi.org/10.1124/jpet.119.256818
Jia, B, Zhao, C, Rakszawski, KL, Claxton, D, Ehmann, WC, Rybka, W, Mineishi, S, Wang, M, Shike, H, Bayerl, M, Sivik, JM, Schell, T, Drabick, J, Hohl, R & Zheng, H 2019, 'Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia', Cancer Research, vol. 79, no. 7, pp. 1635-1645. https://doi.org/10.1158/0008-5472.CAN-18-3107

2018

Jia, B, Wang, L, Claxton, D, Ehmann, WC, Rybka, W, Mineishi, S, Rizvi, S, Shike, H, Bayerl, M, Schell, T, Hohl, R & Zheng, H 2018, 'Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients', Blood Cancer Journal, vol. 8, no. 3, 34. https://doi.org/10.1038/s41408-018-0069-4
Weissenrieder, JS, Reilly, JE, Neighbors, J & Hohl, R 2019, 'Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models', Prostate, vol. 79, no. 1, pp. 21-30. https://doi.org/10.1002/pros.23707
Kokolus, KM, Haley, JS, Koubek, EJ, Gowda, R, Dinavahi, SS, Sharma, A, Claxton, D, Helm, K, Drabick, J, Robertson, G, Neighbors, J, Hohl, R & Schell, T 2019, 'Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity', OncoImmunology, vol. 8, no. 2, e1539614. https://doi.org/10.1080/2162402X.2018.1539614
Koubek, EJ, Weissenrieder, JS, Neighbors, J & Hohl, R 2018, 'Schweinfurthins: Lipid Modulators with Promising Anticancer Activity' Lipids, vol. 53, no. 8, pp. 767-784. https://doi.org/10.1002/lipd.12088
Wang, L, Jia, B, Claxton, D, Ehmann, WC, Rybka, W, Mineishi, S, Naik, S, Khawaja, MR, Sivik, J, Han, J, Hohl, R & Zheng, H 2018, 'VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML' OncoImmunology, vol. 7, no. 9, e1469594. https://doi.org/10.1080/2162402X.2018.1469594

2017

Zhu, L, Kong, Y, Zhang, J, Claxton, D, Ehmann, WC, Rybka, W, Palmisiano, ND, Wang, M, Jia, B, Bayerl, M, Schell, T, Hohl, R, Zeng, H & Zheng, H 2017, 'Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia', Journal of Hematology and Oncology, vol. 10, no. 1, 124. https://doi.org/10.1186/s13045-017-0486-z
Lee, JSH, Blumenthal, GM, Hohl, R & Huang, SM 2017, 'Cancer Therapy: Shooting for the Moon', Clinical pharmacology and therapeutics, vol. 101, no. 5, pp. 552-558. https://doi.org/10.1002/cpt.655
Schoenfeld, JD, Sibenaller, ZA, Mapuskar, KA, Wagner, BA, Cramer-Morales, KL, Furqan, M, Sandhu, S, Carlisle, TL, Smith, MC, Abu Hejleh, T, Berg, DJ, Zhang, J, Keech, J, Parekh, KR, Bhatia, S, Monga, V, Bodeker, KL, Ahmann, L, Vollstedt, S, Brown, H, Shanahan Kauffman, EP, Schall, ME, Hohl, R, Clamon, GH, Greenlee, JD, Howard, MA, Shultz, MK, Smith, BJ, Riley, DP, Domann, FE, Cullen, JJ, Buettner, GR, Buatti, JM, Spitz, DR & Allen, BG 2017, 'O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate', Cancer Cell, vol. 31, no. 4, pp. 487-500.e8. https://doi.org/10.1016/j.ccell.2017.02.018
Reilly, JE, Neighbors, J & Hohl, R 2017, 'Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis', Cancer Biology and Therapy, vol. 18, no. 11, pp. 872-882. https://doi.org/10.1080/15384047.2016.1219817

2016

Hohl, R 2016, 'Anticoagulants: Major Advances Without Clear Consensus', Clinical Pharmacology and Therapeutics, pp. 116-118. https://doi.org/10.1002/cpt.399
Ferguson, SD, Xiu, J, Weathers, SP, Zhou, S, Kesari, S, Weiss, SE, Verhaak, RG, Hohl, R, Barger, GR, Reddy, SK & Heimberger, AB 2016, 'GBM-associated mutations and altered protein expression are more common in young patients', Oncotarget, vol. 7, no. 43, pp. 69466-69478. https://doi.org/10.18632/oncotarget.11617
Raje, NS, Faber, EA, Richardson, PG, Schiller, G, Hohl, R, Cohen, AD, Forero, A, Carpenter, S, Nguyen, TS, Conti, I, Kaiser, CJ, Cronier, DM, Wooldridge, JE & Anderson, KC 2016, 'Phase 1 study of tabalumab, a human anti-B-cell activating factor antibody, and bortezomib in patients with relapsed/refractory multiple myeloma', Clinical Cancer Research, vol. 22, no. 23, pp. 5688-5695. https://doi.org/10.1158/1078-0432.CCR-16-0201

2015

Kuder, CH, Weivoda, MM, Zhang, Y, Zhu, J, Neighbors, J, Wiemer, DF & Hohl, R 2015, '3-Deoxyschweinfurthin B Lowers Cholesterol Levels by Decreasing Synthesis and Increasing Export in Cultured Cancer Cell Lines' Lipids, vol. 50, no. 12, pp. 1195-1207. https://doi.org/10.1007/s11745-015-4083-z
Sheehy, RM, Kuder, CH, Bachman, Z & Hohl, R 2015, 'Calcium and P-glycoprotein independent synergism between schweinfurthins and verapamil' Cancer Biology and Therapy, vol. 16, no. 8, pp. 1259-1268. https://doi.org/10.1080/15384047.2015.1056420
Reilly, JE, Zhou, X, Tong, H, Kuder, CH, Wiemer, DF & Hohl, R 2015, 'In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors' Biochemical Pharmacology, vol. 96, no. 2, pp. 83-92. https://doi.org/10.1016/j.bcp.2015.04.009
Hohl, R 2015, 'Oncology trial design: More accurately and efficiently advancing the field', Clinical Pharmacology and Therapeutics, vol. 97, no. 5, pp. 430-432. https://doi.org/10.1002/cpt.94
Holstein, SA, Bigelow, JC, Olson, RD, Vestal, RE, Walsh, GM & Hohl, R 2015, 'Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors', Investigational New Drugs, vol. 33, no. 3, pp. 594-602. https://doi.org/10.1007/s10637-015-0220-z
Ferguson, NN, Thomas, CP, Hohl, R, Syrbu, SI, Stone, MS & Wanat, KA 2015, 'Primary cutaneous polymorphic ebv-associated posttransplant lymphoproliferative disorder after a renal transplant and review of the literature' American Journal of Dermatopathology, vol. 37, no. 10, pp. 790-794. https://doi.org/10.1097/DAD.0000000000000272
Reilly, JE, Neighbors, J, Tong, H, Henry, MD & Hohl, R 2015, 'Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis' Clinical and Experimental Metastasis, vol. 32, no. 6, pp. 555-566. https://doi.org/10.1007/s10585-015-9727-0
Osborn-Heaford, HL, Murthy, S, Gu, L, Larson-Casey, JL, Ryan, AJ, Shi, L, Glogauer, M, Neighbors, J, Hohl, R & Carter, AB 2015, 'Targeting the isoprenoid pathway to abrogate progression of pulmonary fibrosis', Free Radical Biology and Medicine, vol. 86, pp. 47-56. https://doi.org/10.1016/j.freeradbiomed.2015.04.031

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)